Shionogi Snags Biotech Startup in Massive $2 Billion Rare Disease Power Play
Shionogi just closed a massive $2 billion deal to acquire Texas biotech IntraBio! The Japanese pharma giant is folding the company into its structure, taking full control of AQNEURSA, a drug offering life-changing treatment for several rare neurological disorders.
- Original source: hoodline.com.
- The source published it on Nov 20, 2026 at 5:47 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Shionogi Inc. officially completed its $2 billion acquisition of Texas-based biotech company IntraBio Inc., making a major splash in the rare disease market. The acquisition finished on November 18, turning IntraBio into a wholly owned subsidiary of the Japanese pharmaceutical giant.
AQNEURSA, the drug at the heart of the deal, is a treatment for devastating rare neurological disorders like Niemann-Pick disease type C. The FDA granted the drug approval in 2024, and it received EU approval in January 2026 for the neurological effects of that specific disease.
The drug's influence keeps growing, having received FDA approval in September 2026 as the sole treatment option for ataxia in adults and children with ataxia-telangiectasia. Shionogi is also currently studying AQNEURSA for CACNA1A neurological disorders in a Phase III trial.
The purchase bolsters Shionogi’s pipeline significantly, bringing programs targeting Fragile X syndrome, Pompe disease, and Jordan's syndrome into their portfolio. Financially, IntraBio posted sales of $68 million in 2025, according to BioPharma Dive.
Shionogi officials are thrilled, with CEO Nathan McCutcheon noting that acquisitions like this help build a strong, sustainable presence in the rare disease space. Patient advocacy groups like the A-T Children's Project have welcomed the deal, hoping Shionogi's resources expand access to the treatment.
This massive purchase follows a prior major move earlier this year when Shionogi secured rights to ALS treatments Radicava ORS and IV Radicava in a $2.5 billion deal in April 2026.
Source: hoodline.com
Written by AI from verified reporting.
More stories
- Health & science finance.yahoo.com 1 viewMedtronic's Hugo robot clears FDA for general surgery
- Health & science wired.com 1 viewEl Niño Pushes California's Coastal Waters Off the Charts, and the Storms Are Following
- Health & science biobuzz.io 1 viewFDA approves AstraZeneca's once-weekly Klygefa for generalised myasthenia gravis
- Health & science theguardian.com 2 sources 1 viewPancreatic cancer pill erases tumours in 1 in 12 patients, trial finds

